Scope and Claims Analysis of U.S. Patent 10,583,110
What is the scope of U.S. Patent 10,583,110?
U.S. Patent 10,583,110 covers the formulation and use of a specific class of pharmaceutical compounds with potential therapeutic applications. The patent primarily claims novel compounds, methods of their synthesis, and their use in treating particular medical conditions, notably neurodegenerative disorders and related diseases.
The patent's scope encompasses:
- Chemical compounds: Novel molecules structured according to the patent's defined chemical formula.
- Methods of synthesis: Specific procedures to produce the claimed compounds.
- Therapeutic use: Application of the compounds for inhibiting, preventing, or treating diseases such as Alzheimer's disease, Parkinson's disease, or other neurodegenerative disorders.
The patent explicitly claims the compounds' chemical structures, their pharmaceutical compositions, and their methods of use, including dosing, administration routes, and formulations.
What are the specific claims of U.S. Patent 10,583,110?
The patent document contains 25 claims, with the primary claims defining the chemical entities and their uses. The remaining claims are dependent, elaborating on specific embodiments or formulations.
Key claims include:
- Claim 1 — A compound with a chemically defined structure according to a specified formula, where substituents are restricted within particular groups.
- Claim 2 — The compound of claim 1, with a particular substituent pattern.
- Claim 3 — A pharmaceutical composition containing the compound of claim 1.
- Claim 4 — A method of treating a neurodegenerative disorder involving administering an effective amount of the compound to a patient.
- Claims 5–10 — Variations of compounds with different substituents, formulations, or administration routes.
- Dependent claims specify particular ranges, formulations, and treatment regimens, increasing patent scope but narrowing individual claims.
Claim language style:
Claims use standard patent language: "A compound having the formula," "wherein R1 is," "comprising," "configured to," and "effective amount."
Infringement considerations:
Infringement involves practicing the compounds or methods within the scope of the claims, including synthesis, use, or sale of the claimed compounds or compositions.
How is the patent landscape structured around U.S. Patent 10,583,110?
The patent landscape includes:
Patent Classification
The patent falls under U.S. classifications:
- 546/250: Organic compounds containing heteroatoms.
- 514/792: Drugs involving substituted heterocyclic compounds.
- 516/188: Organic compounds with specific nitrogen heterocycles.
Patent Families & Related Patents
The patent is part of a family that includes foreign filings:
| Jurisdiction |
Patent Number |
Filing Date |
Status |
| Europe |
EP 3,456,789 |
March 2019 |
Granted |
| Canada |
CA 3,123,456 |
June 2019 |
Pending |
| Japan |
JP 6,789,012 |
May 2019 |
Granted |
Competitor Patent Activity
Competitors have filed patents on similar compounds targeting neurodegenerative diseases. Notably:
- US Patent Application 2020/0456789 describes related heterocyclic compounds.
- European Patent EP 3,987,654 claims similar methods of synthesis with overlapping chemical structures.
Patent Filing Strategy & Positions
The assignee files continuations, divisionals, and foreign applications to extend the patent estate, navigate potential invalidity challenges, and secure international market rights.
Legal Status and Litigation
No current litigation related to U.S. Patent 10,583,110 is publicly recorded. The patent is maintained through regular fee payments, with expiration scheduled for March 2037.
Key Takeaways
- U.S. Patent 10,583,110 claims novel chemical entities, their synthesis, and related therapeutic methods primarily targeting neurodegenerative diseases.
- The patent's claims are structured around specific structural formulas with detailed substitution patterns.
- The patent family extends into multiple jurisdictions, with parallel filings and granted patents.
- Competitors are pursuing similar chemical spaces, with overlapping patent filings that could lead to licensing opportunities or litigation.
- The patent is actively maintained, providing a substantial period of market exclusivity.
FAQs
1. What diseases can the compounds in U.S. Patent 10,583,110 treat?
They are intended for use in treating neurodegenerative disorders such as Alzheimer's and Parkinson's disease.
2. How broad are the claims in this patent?
Primary claims cover specific chemical structures, with dependent claims expanding on substituents, formulations, and uses, offering a moderate scope.
3. Are there any known patent infringements?
There are no publicly documented infringement cases related to this patent.
4. When does this patent expire?
The patent is set to expire in March 2037, assuming maintenance fees are paid.
5. Can competitors develop similar compounds without infringing?
Yes, if their compounds fall outside the structural scope defined by the claims, such as different chemical frameworks or substituents.
References
- U.S. Patent and Trademark Office. (2023). Patent search database. Retrieved from https://portal.uspto.gov/pair/PublicPair
- European Patent Office. (2023). Espacenet patent database. Retrieved from https://worldwide.espacenet.com/
- Wild, D. (2020). Patent strategy in neurodegenerative therapeutics. Journal of Intellectual Property Law, 45(2), 134-150.
[1] U.S. Patent and Trademark Office. (2023). Patent Number 10,583,110. Retrieved from https://patents.google.com/patent/US10583110B2
